Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of simeprevir versus telaprevir with peginterferon alfa-2a and ribavirin in chronic hepatitis C genotype 1 infection
2011-001180-53Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatitis C virus infection comparing Simeprevir + peginterferon alfa-2a + ribavirin with Telaprevir + peginterferon alfa-2a + ribavirin (2 arms). Primary endpoint: SVR12. Started Nov 2011; status: completed.
02
Drugs
simeprevirtelaprevirpeginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2011-001180-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001180-53.